Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
第一作者:
William,Towner
第一单位:
Kaiser Permanente-Infectious Diseases, Los Angeles, CA 90027, USA. william.j.towner@kp.org
作者:
医学主题词
成年人(Adult);抗HIV药(Anti-HIV Agents);CD4淋巴细胞计数(CD4 Lymphocyte Count);女(雌)性(Female);HIV感染(HIV Infections);HIV-1(HIV-1);人类(Humans);男(雄)性(Male);中年人(Middle Aged);腈类(Nitriles);哒嗪类(Pyridazines);嘧啶类(Pyrimidines);吡咯烷酮类(Pyrrolidinones);利托纳韦(Ritonavir);磺胺类(Sulfonamides);美国(United States);病毒载量(Viral Load)
DOI
10.1097/QAI.0b013e3181cdebb1
PMID
20134329
发布时间
2020-12-09
- 浏览14
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



